Annexon, Inc. (NASDAQ:ANNX) Short Interest Update

Annexon, Inc. (NASDAQ:ANNX - Get Free Report) was the target of a large increase in short interest in January. As of January 31st, there was short interest totalling 10,090,000 shares, an increase of 8.3% from the January 15th total of 9,320,000 shares. Based on an average trading volume of 1,420,000 shares, the days-to-cover ratio is presently 7.1 days.

Annexon Stock Performance

NASDAQ:ANNX traded down $0.02 on Thursday, hitting $2.83. The stock had a trading volume of 796,392 shares, compared to its average volume of 1,392,694. The stock has a market cap of $301.65 million, a P/E ratio of -2.70 and a beta of 1.07. Annexon has a 1 year low of $2.63 and a 1 year high of $8.40. The firm's fifty day simple moving average is $4.29 and its two-hundred day simple moving average is $5.57.

Wall Street Analyst Weigh In

ANNX has been the topic of several recent research reports. HC Wainwright reaffirmed a "buy" rating and issued a $30.00 price target on shares of Annexon in a research report on Tuesday, December 17th. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Annexon in a research report on Friday, November 15th. Finally, Needham & Company LLC reaffirmed a "buy" rating and issued a $16.00 price target on shares of Annexon in a research report on Friday, November 15th. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Annexon presently has a consensus rating of "Buy" and a consensus price target of $15.80.

Institutional Investors Weigh In On Annexon

Several institutional investors and hedge funds have recently added to or reduced their stakes in ANNX. State Street Corp increased its stake in shares of Annexon by 116.6% during the 3rd quarter. State Street Corp now owns 3,841,879 shares of the company's stock worth $22,744,000 after purchasing an additional 2,068,294 shares during the last quarter. Sio Capital Management LLC purchased a new stake in shares of Annexon during the 3rd quarter worth approximately $8,484,000. Sphera Funds Management LTD. purchased a new stake in shares of Annexon during the 4th quarter worth approximately $6,377,000. Ameriprise Financial Inc. increased its stake in shares of Annexon by 483.6% during the 4th quarter. Ameriprise Financial Inc. now owns 926,642 shares of the company's stock worth $4,754,000 after purchasing an additional 767,869 shares during the last quarter. Finally, TFG Asset Management GP Ltd increased its stake in shares of Annexon by 78.5% during the 4th quarter. TFG Asset Management GP Ltd now owns 1,400,000 shares of the company's stock worth $7,182,000 after purchasing an additional 615,645 shares during the last quarter.

Annexon Company Profile

Annexon, Inc, a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis.